Schairer Catherine, Mink Pamela J, Carroll Leslie, Devesa Susan S
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
J Natl Cancer Inst. 2004 Sep 1;96(17):1311-21. doi: 10.1093/jnci/djh253.
Among cancer patients, probabilities of death from that cancer and other causes in the presence of competing risks are optimal measures of prognosis and of mortality across demographic groups. We used data on breast cancer patients from the Surveillance, Epidemiology, and End Results (SEER) Program in a competing-risk analysis.
We determined vital status and cause of death for 395,251 white and 35,259 black female patients with breast cancer diagnosed from January 1, 1973, through December 31, 2000, by use of SEER data. We calculated probabilities of death from breast cancer and other causes according to stage, race, and age at diagnosis; for cases diagnosed from January 1, 1990, to December 31, 2000, we also calculated some such probabilities according to tumor size and estrogen receptor (ER) status. All statistical tests were two-sided.
The probability of death from breast cancer after nearly 28 years of follow-up ranged from 0.03 to 0.10 for patients with in situ disease to 0.70 to 0.85 for patients with distant disease, depending on race and age. The probability of death from breast cancer at the end of the follow-up period generally declined with age at diagnosis; the probability among the oldest (> or =70 years) compared with the youngest (<50 years) patients was 33% lower for white and 46% lower for black patients with localized disease and 14% lower for white patients and 13% lower for black patients with distant disease. The probability of death from breast cancer exceeded that from all other causes for patients diagnosed with localized disease before age 50 years, with regional disease before age 60 years, and with distant disease at any age. The probability of death from breast cancer for patients diagnosed with localized or regional disease was statistically significantly greater in black patients than in white patients (all six P values < or =.01 for age groups 30-49 to 60-69 years; two P values < or =.04 for ages > or =70 years). Among patients with localized or regional disease and known ER status, the probability of death from breast cancer after nearly 11 years of follow-up ranged from 0.04 to 0.11 for patients with localized ER-positive tumors of 2 cm or less to 0.37 to 0.53 for patients with regional ER-negative tumors.
The probability of death from breast cancer versus other causes varied substantially according to stage, tumor size, ER status, and age at diagnosis in both white and black patients.
在癌症患者中,存在竞争风险时死于该癌症及其他原因的概率是各人口群体预后和死亡率的最佳衡量指标。我们在一项竞争风险分析中使用了监测、流行病学和最终结果(SEER)计划中乳腺癌患者的数据。
我们利用SEER数据确定了1973年1月1日至2000年12月31日期间诊断为乳腺癌的395251名白人女性患者和35259名黑人女性患者的生命状态和死亡原因。我们根据诊断时的分期、种族和年龄计算死于乳腺癌和其他原因的概率;对于1990年1月1日至2000年12月31日期间诊断的病例,我们还根据肿瘤大小和雌激素受体(ER)状态计算了一些此类概率。所有统计检验均为双侧检验。
经过近28年的随访,原位疾病患者死于乳腺癌的概率为0.03至0.10,远处疾病患者为0.70至0.85,具体取决于种族和年龄。随访期末死于乳腺癌的概率通常随诊断时年龄的增加而下降;与最年轻(<50岁)患者相比,年龄最大(≥70岁)的白人局限性疾病患者死于乳腺癌的概率低33%,黑人患者低46%;白人远处疾病患者低14%,黑人患者低13%。50岁前诊断为局限性疾病、60岁前诊断为区域性疾病以及任何年龄诊断为远处疾病的患者,死于乳腺癌的概率超过死于所有其他原因的概率。诊断为局限性或区域性疾病的患者中,黑人患者死于乳腺癌的概率在统计学上显著高于白人患者(30 - 49岁至60 - 69岁年龄组的所有六个P值≤0.01;≥70岁年龄组的两个P值≤0.04)。在已知ER状态的局限性或区域性疾病患者中,经过近11年的随访,局限性ER阳性肿瘤直径2 cm或更小的患者死于乳腺癌的概率为0.04至0.11,区域性ER阴性肿瘤患者为0.37至0.53。
在白人和黑人患者中,死于乳腺癌与其他原因的概率根据分期、肿瘤大小、ER状态和诊断时年龄有很大差异。